ECPAS and breast carcinoma: To characterize the potential role of ECM29 as a mediator of palbociclib effects in breast cancer, we examined the potential breast cancer association of ECM29 through the publicly available gene expression data on relapse‐free breast cancer patient survival (Gyorffy et al, 2010).